Experts in core dermatological specialties share their insights on the game-changing research and innovation that advancing skin disease management and patient care.
Opening the session "What’s New in Dermatology" at the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), session leader Mark Lebwohl, MD, pointed out that not even COVID-19 could stop innovation in dermatology.
“Despite the pandemic, there have been many breakthroughs in our specialty,” said Lebwohl, Dean for Clinical Therapeutics and Chairman emeritus at the Kimberly and Eric J. Waldman Department of Dermatology in the Icahn School of Medicine at Mount Sinai in New York, New York, and a member of Dermatology Times®’ editorial advisory board.
This year will build on that, he added. Lebwohl and other key opinion leaders across the specialty highlighted the research, treatments, and techniques that will continue to shorten the distance between skin disease management and cure during their presentations at the AAD’s annual meeting held virtually April 23-25, 2021.1
Here is their list of top trends to watch.
Because this is a synthetic analogue of the amino acid lysine, it competitively inhibits the transformation of plasminogen to plasma, a molecule that degrades fibrin. “Via multiple steps, tranexamic acid blocks the production of inflammatory mediators like prostaglandins and arachidonic acid,” he said. “And guess what prostaglandins and arachidonic acid do in melasma pigmentation? They stimulate tyrosyl activity to make more melanin.”
While there are some contraindications to oral tranexamic acid for patients who are pregnant, nursing or breastfeeding, “young healthy male and female patients can use this for recalcitrant disease,” Desai said. “I use it frequently in 250 mg to 500 mg doses VID or BID. I typically do this to see improvement in 6 to 8 weeks.”
Lebwohl receives research funds Abbvie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly,Incyte, Janssen Research & Development, LLC,Leo Pharmaceutucals,Ortho Dermatologics, Pfizer, and UCB, Inc.and is a consultant for Aditum Bio, Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., BMD skincare, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Kyowa Kirin, LEO Pharma, Meiji Seika Pharma,Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica. Rigel mentioned Castle BioSciences, SciBase, Molesafe and DermTech. Boh reported financial disclosures from Ortho Dermatologics, Incyte, Corrona, UCB, Abbvie, Janssen, Pfizer. Desai reported no relevant or financial disclosures.
1. Lebwohl M, Rigel D, Boh E. What’s new in dermatology. Presented at: American Academy of Dermatology 2021 Virtual Meeting Experience (VMX) annual meeting; April 23-25, 2021.
2. Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet 2020; 396: 110–20